TREATMENT OF A CHRONIC OBSTRUCTIVE PULMONARY DISEASE CASE WITH REGENTIME® PROCEDURE

Authors

  • Rita T. Boulos Medical Doctor, ACE Cells Lab Ltd, United Kingdom.
  • Lea I. Nemer Molecular Biology, University of Balamand, Lebanon
  • Vanessa J. Mansour Infectious Diseases and Immunology, University of Balamand, Lebanon.
  • Nassim H. Abi Chahine Neurological Surgery, University of Lodz, Poland and University of Balamand, Lebanon.

Keywords:

Regentime® Procedure, Bone Marrow-Mesenchymal Stem Cells, Chronic Obstructive Pulmonary Disease.

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a common disease associated with high morbidity and mortality rates. It is characterized by airway and parenchymal inflammation leading to airway narrowing, decreased lung recoil, and eventual airflow limitation. Despite the advance in therapeutic approaches, no curative clinical treatment for COPD exists. We present the case of a 74-year-old gentleman diagnosed with COPD who underwent stem cell therapy with the Regentime® Procedure. This technique uses Autologous Bone Marrow -Mononuclear Stem Cells (BM-MSCs) which are partially differentiated and specifically redirected to the desired organ. Clinical follow-up 5 years after transplantation showed a decrease in major symptoms, including dyspnea, cough, fatigue, and decreased oxygen requirement.  However, regression was registered during the past 2 years during which the patient’s oxygen requirement increased for optimal oxygen saturation. The results obtained support stem cell-based therapy as a promising therapeutic option for patients suffering from COPD.

Downloads

Published

-

How to Cite

Rita T. Boulos, Lea I. Nemer, Vanessa J. Mansour, & Nassim H. Abi Chahine. (2022). TREATMENT OF A CHRONIC OBSTRUCTIVE PULMONARY DISEASE CASE WITH REGENTIME® PROCEDURE. EPRA International Journal of Research and Development (IJRD), 7(7), 57–60. Retrieved from http://www.eprajournals.net/index.php/IJRD/article/view/679